(NYSEMKT: OCX) ONCOCYTE's forecast annual revenue growth rate of 149.75% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.86%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.39%.
ONCOCYTE's revenue in 2022 is $8,027,000.On average, 1 Wall Street analysts forecast OCX's revenue for 2022 to be $3,105,041,150, with the lowest OCX revenue forecast at $3,105,041,150, and the highest OCX revenue forecast at $3,105,041,150. On average, 1 Wall Street analysts forecast OCX's revenue for 2023 to be $5,333,085,945, with the lowest OCX revenue forecast at $5,333,085,945, and the highest OCX revenue forecast at $5,333,085,945.
In 2024, OCX is forecast to generate $9,362,528,659 in revenue, with the lowest revenue forecast at $9,362,528,659 and the highest revenue forecast at $9,362,528,659.